Type 2 diabetic acute myocardial infarction (AMI) patients receiving sodium-glucose cotransporter 2 inhibitors (SGLT2-I) exhibited a significantly reduced inflammatory response. Here, SLC5A2 is linked to acute myocardial infarction.